Vanda Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held on June 4, 2026. The filing was submitted on June 5, 2026. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Global Market under the symbol VNDA.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Voting Results
Of the 60,135,062 shares entitled to vote, 48,509,906 shares (approximately 80.7%) were represented, constituting a quorum. The following proposals were approved:
- Proposal 1 (Election of Directors): Three Class II directors were elected to serve until the 2029 annual meeting.
- Richard W. Dugan: 33,029,049 votes for; 5,417,322 votes against.
- Charles C. Duncan, Ph.D.: 35,780,031 votes for; 2,664,889 votes against.
- Anne Sempowski Ward: 33,897,782 votes for; 4,543,488 votes against.
- Proposal 2 (Ratification of Auditor): Stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Votes For: 48,103,698
- Votes Against: 340,513
- Proposal 3 (Executive Compensation): Stockholders approved the advisory vote on named executive officer compensation.
- Votes For: 35,242,659
- Votes Against: 3,167,243
- Proposal 4 (Equity Plan Amendment): Stockholders approved an amendment to the Amended and Restated 2016 Equity Incentive Plan to increase the aggregate number of shares authorized for issuance.
- Votes For: 31,729,991
- Votes Against: 6,685,078
Guidance, Outlook, and Risks
This filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It references the definitive proxy statement on Schedule 14A filed on April 23, 2026, for further details on the proposals.
Investor Verification Checklist
- Verify the specific number of shares added to the 2016 Equity Incentive Plan by reviewing the Schedule 14A Proxy Statement.
- Review the Schedule 14A Proxy Statement for detailed biographies of the newly elected directors and the rationale for the equity plan amendment.
- Confirm the Company's upcoming financial reporting schedule, as this 8-K does not include financial results.